Smith reminds investors that class action lawsuits ... and/or misleading statements and/or failed to disclose that: (1) GSK was fully aware of the source of NDMA and had been for nearly 40 years ...

Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against GSK plc. ("GSK" or the "Company") (NYSE: GSK). IF YOU ARE AN ...

After 2 positive trials, low-dose colchicine’ got the FDA nod for CV reduction but then the CLEAR SYNERGY trial found no ...

Data from the Phase II trial saw three of the seven patients dosed with CAN-2409 surviving for more than 35 months.

GSK has said that its chief financial officer ... having previously held roles at UK drugmaker AstraZeneca and medical device player Smith & Nephew, as well as serving as a non-executive director ...

The one-time leader of the DNA analysis market – valued at $6 billion in 2021 – is now worth less than $100 million, a 99 ...

Hippodrome employees Jo and Steve will run London Marathon to raise funds for a children's hospice ...

The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

Bristol-based charity Nilaari Agency has won a major impact award for supporting ethnically marginalised communities. Bristol24/7 charity partner for 2024/2025, Nilaari Agency, has scooped one of this ...

The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Rocket Lab USA, Inc. ("Rocket Lab" or the ...

The role of AI in supply chain management proved to be the focal issue at the recent 2025 Clinical Trial Supply Europe ...